LILRB1 and neoplasm: Among these genes, ILT2 was down-regulated in the tumor of clinically responding patients and up-regulated in non-responders (Figure 2B), suggesting that ILT2 may be a predictive biomarker of response to oncolytic vaccinia virus treatment.